[go: up one dir, main page]

CY1112390T1 - Διαδικασια και ενδιαμεσα παρασκευης παραγωγων της ν-(1-βενζυδρυλ-αζετιδιν-3-υλ)-ν-φαινυλ-μεθυλσουλφοναμιδης - Google Patents

Διαδικασια και ενδιαμεσα παρασκευης παραγωγων της ν-(1-βενζυδρυλ-αζετιδιν-3-υλ)-ν-φαινυλ-μεθυλσουλφοναμιδης

Info

Publication number
CY1112390T1
CY1112390T1 CY20121100184T CY121100184T CY1112390T1 CY 1112390 T1 CY1112390 T1 CY 1112390T1 CY 20121100184 T CY20121100184 T CY 20121100184T CY 121100184 T CY121100184 T CY 121100184T CY 1112390 T1 CY1112390 T1 CY 1112390T1
Authority
CY
Cyprus
Prior art keywords
azetidin
methylsulphonamid
benzydyryl
fenyl
intermediates
Prior art date
Application number
CY20121100184T
Other languages
English (en)
Inventor
Philippe Boffelli
Michel Delthil
Luc Grondard
Maxime Lampilas
Joёl Malpart
Stéphane Mutti
Bouda Lahlou Nait
Joerg Rieke-Zapp
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of CY1112390T1 publication Critical patent/CY1112390T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Νέα διαδικασία σύνθεσης της Ν-{1-[bis-(4-χλωροφαινυλ)μεθυλ]αζετιδιν-3-υλ}-Ν-(3,5-διφθοροφαινυλ)-μεθυλ-σουλφοναμίδης.
CY20121100184T 2004-10-14 2012-02-23 Διαδικασια και ενδιαμεσα παρασκευης παραγωγων της ν-(1-βενζυδρυλ-αζετιδιν-3-υλ)-ν-φαινυλ-μεθυλσουλφοναμιδης CY1112390T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0410845A FR2876689B1 (fr) 2004-10-14 2004-10-14 Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
EP05809316A EP1802571B1 (fr) 2004-10-14 2005-10-10 Procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide

Publications (1)

Publication Number Publication Date
CY1112390T1 true CY1112390T1 (el) 2015-12-09

Family

ID=34953744

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100184T CY1112390T1 (el) 2004-10-14 2012-02-23 Διαδικασια και ενδιαμεσα παρασκευης παραγωγων της ν-(1-βενζυδρυλ-αζετιδιν-3-υλ)-ν-φαινυλ-μεθυλσουλφοναμιδης

Country Status (32)

Country Link
US (3) US7429668B2 (el)
EP (1) EP1802571B1 (el)
JP (1) JP4971986B2 (el)
KR (1) KR20070063540A (el)
CN (1) CN101039903A (el)
AR (1) AR051389A1 (el)
AT (1) ATE534624T1 (el)
AU (1) AU2005293453A1 (el)
BR (1) BRPI0516526A (el)
CA (1) CA2581781A1 (el)
CR (1) CR9008A (el)
CY (1) CY1112390T1 (el)
DK (1) DK1802571T3 (el)
EA (2) EA012523B1 (el)
ES (1) ES2378181T3 (el)
FR (1) FR2876689B1 (el)
HR (1) HRP20120168T1 (el)
IL (1) IL182277A0 (el)
MA (1) MA29005B1 (el)
ME (1) ME01297B (el)
MX (1) MX2007004483A (el)
NO (1) NO20072431L (el)
PL (1) PL1802571T3 (el)
PT (1) PT1802571E (el)
RS (1) RS52132B (el)
SG (2) SG144921A1 (el)
SI (1) SI1802571T1 (el)
TN (1) TNSN07115A1 (el)
TW (1) TW200626542A (el)
UY (1) UY29165A1 (el)
WO (1) WO2006040464A1 (el)
ZA (1) ZA200703011B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2925050B1 (fr) * 2007-12-14 2010-01-08 Sanofi Aventis Nouveau procede de preparation de derives d'azetidine
JP5599878B2 (ja) * 2009-06-29 2014-10-01 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー １−アミノ−１，３，３，５，５−ペンタメチルシクロヘキサンを調製する方法
PL2448910T3 (pl) * 2009-06-29 2013-10-31 Merz Pharma Gmbh & Co Kgaa Sposób wytwarzania nerameksanu
CN107089918B (zh) * 2017-04-08 2020-06-16 迪嘉药业集团有限公司 一种盐酸二苯甲胺的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714129D0 (en) * 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite

Also Published As

Publication number Publication date
ATE534624T1 (de) 2011-12-15
EA200700842A1 (ru) 2007-08-31
JP4971986B2 (ja) 2012-07-11
UY29165A1 (es) 2006-05-31
FR2876689B1 (fr) 2008-02-22
EP1802571A1 (fr) 2007-07-04
HRP20120168T1 (hr) 2012-03-31
PT1802571E (pt) 2012-03-05
CN101039903A (zh) 2007-09-19
US20100087414A1 (en) 2010-04-08
DK1802571T3 (da) 2012-03-12
JP2008516931A (ja) 2008-05-22
PL1802571T3 (pl) 2012-04-30
CR9008A (es) 2007-10-01
TW200626542A (en) 2006-08-01
AU2005293453A1 (en) 2006-04-20
US7429668B2 (en) 2008-09-30
EA012523B1 (ru) 2009-10-30
US20080312205A1 (en) 2008-12-18
ME01297B (me) 2013-12-20
MA29005B1 (fr) 2007-11-01
NO20072431L (no) 2007-07-04
US8071788B2 (en) 2011-12-06
RS52132B (sr) 2012-08-31
WO2006040464A1 (fr) 2006-04-20
ES2378181T3 (es) 2012-04-09
BRPI0516526A (pt) 2008-09-09
US20070244084A1 (en) 2007-10-18
SI1802571T1 (sl) 2012-03-30
TNSN07115A1 (fr) 2008-06-02
SG144921A1 (en) 2008-08-28
MX2007004483A (es) 2007-06-13
CA2581781A1 (fr) 2006-04-20
FR2876689A1 (fr) 2006-04-21
IL182277A0 (en) 2007-07-24
SG144920A1 (en) 2008-08-28
AR051389A1 (es) 2007-01-10
ZA200703011B (en) 2009-09-30
KR20070063540A (ko) 2007-06-19
EP1802571B1 (fr) 2011-11-23
US7652154B2 (en) 2010-01-26
EA200801990A1 (ru) 2009-06-30

Similar Documents

Publication Publication Date Title
CY1106486T1 (el) Μεθοδος παρασκευης 2-(κινοξαλιν-5-υλσουλφονυλαμινο) βενζαμιδικων ενωσεων
ATE543807T1 (de) Verstärker von glutamat-rezeptoren
MX2023002890A (es) Procesos e intermedios para la preparacion de (s)-5-amino-3-(4-((5-fluoro-2-metoxibenzamido)metil)fenil)-1-(1,1 ,1-trifluoropropan-2-il)-1h-pirazol-4-carboxamida.
CY1114284T1 (el) Σουλφονυλοπυρρολες ως hdac αναστολεις
CY1107924T1 (el) Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
IL180147A0 (en) N - (1 - (1 - benzyl - 4 - phenyl - 1h-imidazol - 2 - yl) - 2,2 - dymethylpropyl) benzamide derivatives and related compounds as kinesin spidle protein (ksp) inhibitors for the treatment of cancer
ATE459603T1 (de) Pyridinaminosulfonylsubstituierte benzamide als inhibitoren von cytochrom p450 3a4 (cyp3a4)
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
NO20043842L (no) Nye krystallformer av atorvastatinhemikalsium og fremgangsmater for fremstilling derav, savel som nye fremgangsmater for fremstilling av atorvastatinhemikalsiumform I, VIII og IX
CY1112390T1 (el) Διαδικασια και ενδιαμεσα παρασκευης παραγωγων της ν-(1-βενζυδρυλ-αζετιδιν-3-υλ)-ν-φαινυλ-μεθυλσουλφοναμιδης
ITMI20050801A1 (it) Procedimento per la preparazione di telmisartan
TW200745039A (en) Isotopically substituted pantoprazole
ITMI20020991A0 (it) Procedimento per la sintesi del modafinil
AU2003235814A8 (en) Novel process for the preparation of trans-3- ethyl-2,5- dihydro-4- methyl-n-(2-( 4-(((((4-methyl cyclohexyl) amino)carbonyl) amino)sulfonyl) phenyl)ethyl) -2-oxo-1h-pyrrole -1-carboxamide
ATE327987T1 (de) Methylthiophencarboxanilide
NO20072192L (no) Nytt produkt, fremgangsmate og mellomprodukter for fremstilling av azetidinderivater
SG145572A1 (en) Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same
HK40088491A (en) Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1h-pyrazole-4-carboxamide
UY29166A1 (es) Nuevo producto, procedimiento e intermediarios de preparación de derivados de azetidina
CY1110117T1 (el) Μεθοδοι για την παρασκευη ν-(2-ακετυλ-4,6-διμεθυλοφαινυλ)-3-{[3,4 διμεθυλ-5-ισοξαζολυλ)αμινοσουλφονυλ}-2-θειοφαινοκαρβοξαμιδιου